🌿 Singapore's Pioneer in Metabolic Health
Founded in 2019, we combine 20+ years of R&D with nature's wisdom to develop:
• The world's first patented natural strains for cellular health
• Clinically studied ingredients targeting metabolic balance
• 100% natural, traceable ingredients with international Invention patents
🔬 Our Science: Cellular Health Starts Here
"Imagine insulin as your body's energy manager..."
1️⃣ Beta Cells → Produce insulin to regulate glucose
2️⃣ Insulin Resistance → Cells stop responding efficiently
3️⃣ EFILA's Approach → Supports cellular vitality and metabolic function
Our Founders
👨🔬 Dr. Kim | Chief Scientist
• PhD, Western California Medical University
• 30+ years in biotech R&D | 8 invention patents
• EURO INVENT Award winner | Korean Technology Assessment Committee
👨💼 James | CEO & Patient Advocate
• Type 2 diabetic for 20+ years
• Serial entrepreneur focused on transformative health tech
• Mission: "To make cellular health accessible globally"
Mission & Vision
🌟 Mission
To harness nature's pharmacy through biotechnology, delivering:
✓ Scientifically validated wellness solutions
✓ Hope for metabolic health challenges
✓ Patent-protected formulations
🚀 Vision
Redefine global diabetes care by 2030 through:
• Cutting-edge β-cell support research
• ASEAN-focused accessible solutions
• Prevention-first philosophy
🌿 100% Traceable Ingredient
Our signature EFILA® complex contains:
• β-Glucan (35-42% purity) - Metabolic support
• EPS (Exopolysaccharides) - Cellular communication
• Mannose - Gut microbiome nourishment
• 20+ Trace Elements - Pine-derived minerals
TOXICITY AND SAFETY TESTS
Since the beginning of the research, there has been multiple clinical tests done including:
- 5 general toxicity tests
- 3 genetic toxicity tests
- 2 efficacy tests
- 3 safety pharmacology tests.
|
Type of
experiment
|
No.
|
Name of experiment
|
Results
|
|
General
toxicity study
(5 items)
|
1
|
Utilize Beagle dogs for repeated oral administration of DRF experiment for 4 weeks.
|
Non-toxic
|
|
2
|
Utilize Beagle dogs for repeated oral administration in a 13-week toxicity study and a 4-week recovery study.
|
Non-toxic
|
|
3
|
Utilize Sprague-Dawley rats for a single oral dose toxicity study.
|
Non-toxic
|
|
4
|
Utilize Sprague-Dawley rats for a 4-week repeated oral dose toxicity study of DRF.
|
Non-toxic
|
|
5
|
Utilize Sprague-Dawley rats for a 13-week repeated oral dose toxicity study and a 4-week recovery study.
|
Non-toxic
|
|
Genetic
toxicity study (3 items)
|
6
|
Utilize bacterial revertant mutation assays (Salmonella typhimurium, Escherichia coli).
|
Negative
|
|
7
|
Utilize CHL cell chromosomal aberration assay.
|
Negative
|
|
8
|
Utilize male ICR mouse bone marrow micronucleus assay by oral administration
|
Negative
|
|
Efficacy experiments
(2 items)
|
9
|
Utilize ICR mice for a single oral glucose tolerance test (OGTT) efficacy experiment.
|
Observed meaningful
reduction in blood sugar
|
|
10
|
3-week oral administration efficacy experiment for blood glucose reduction in db/db mice
|
Observed meaningful
reduction in blood sugar
|
|
Non-rodent
repeated dose
toxicity and
safety
pharmacology
experiments
(3 items)
|
11
|
Single oral dose central nervous system safety pharmacology experiment in ICR mice
|
No effect ion safety
|
|
12
|
Evaluation experiment on the effects involving the cardiovascular system using a remote testing device after single oral administration in male Beagle dogs (conducted at the Safety Evaluation Research Institute, Korea Research Institute of Chemical Technology).
|
No effect ion safety
|
|
13
|
Evaluation experiment on the impact of hERG Potassium Channel using CHO hERG Cells (conducted at the Safety Evaluation Research Institute, Korea Research Institute of Chemical Technology).
|
No effect ion safety
|
CLINICAL STUDIES
Published five research papers, from in vitro, in vivo to clinical research results, concluded that CL is effective in the treatment of diabetes, and studied its mechanism.
|
1
|
Crude extract of Ceriporia lacerata has a protective effect on dexamethasone-induced cytotoxicity in INS-1 cells via the modulation of PI3K/PKB activity
|
|
2
|
Hypoglycemic effects of submerged culture of Ceriporia lacerata mycelium
|
|
3
|
Effect of submerged culture of Ceriporia lacerata mycelium on GLUT4 protein in db/db mouse
|
|
4
|
Effect of Submerged Culture of Ceriporia lacerata Mycelium on Insulin Signaling Pathway in 3T3-L1 Cell
|
|
5
|
Production of exopolysaccharides by submerged culture of Ceriporia lacerata and their anti-diabetic effect
|
THE MARK OF SAFETY
All the supplements developed and manufactured by Longrunn Medical Technologies are manufactured in a FDA approved facility. Our facilities have also passed stringent checks to ensure that products are manufactured in accordance to best practices.
